Trial intelligence / Profile preview

Methotrexate plus adalimumab for Meniere's disease: pilot single-arm study

ChiCTR2400086895Phase 4Not yet recruiting

Sponsor
Shandong Second Provincial General Hospital
Start
Jul 2024
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of adalimumab and methotrexate in Meniere Disease, sponsored by Shandong Second Provincial General Hospital. Primary endpoints: Safety and Number of vertigo episodes in 3 months. Planned start Jul 2024; status: not yet recruiting.

02

Drugs

adalimumabmethotrexate
03

Conditions

Meniere Disease

Beyond the preview

Go deeper on ChiCTR2400086895.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2400086895.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call